Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol Long-term Safety in Pediatric Crohn's Disease
NCT01190410Phase 2Completed
- Sponsor
- UCB
- Start
- Aug 2010
- Primary completion
- Nov 2017
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
Phase 2, open-label trial of certolizumab pegol in Crohn's disease (2 arms), sponsored by UCB. Primary endpoint: Treatment-Emergent Adverse Events up to 303 weeks. Started Aug 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01190410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01190410.